Clinical Trial

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

Study acronym: RHEA-1
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2028-02-25 -> 2027-06-30 2026-08-14
Trial Details
NCT Number NCT06795022
Lead Sponsor AstraZeneca
Conditions Hepatocellular Carcinoma
Enrollment 304 participants
Start Date 2025-03-27
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13